AstraZeneca requests emergency use authorization for COVID-19 prophylaxis treatment
AstraZeneca today said it has requested an emergency use authorization from the Food and Drug Administration for its long-acting antibody combination for the prevention of symptomatic COVID-19. According to AstraZeneca, phase 3 trial data showed that AZD7442, when administered pre-exposure as prophylaxis, reduced the risk of developing symptomatic COVID-19 by 77%.
Related News Articles
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…